Epigenome-wide methylation in DNA from peripheral blood as a marker of risk for breast cancer
Gianluca Severi, Melissa C Southey, Dallas R English, Chol-hee Jung, Andrew Lonie, Catriona McLean, Helen Tsimiklis, John L Hopper, Graham G Giles, Laura Baglietto
BREAST CANCER RESEARCH AND TREATMENT | SPRINGER | Published : 2014
Aberrant DNA methylation is a key feature of breast carcinoma. We aimed to test the association between breast cancer risk and epigenome-wide methylation in DNA from peripheral blood. Nested case-control study within the prospective Melbourne Collaborative Cohort Study. DNA was extracted from before-diagnosis blood samples (420 incident cases and matched controls). Methylation was measured with the Illumina Infinium Human Methylation 450 BeadChip array. Odds ratio (OR) for epigenome-wide methylation, quantified as the mean beta values across the CpGs, in relation to breast cancer risk were estimated using conditional logistic regression. Overall, the OR for breast cancer was 0.42 (95% CI 0.2..View full abstract
Awarded by National Health and Medical Research Council
We would like to express our gratitude to the many thousands of Melbourne residents who continue to participate in the Melbourne Collaborative Cohort Study, the original investigators, program managers and the diligent team who recruited the participants and who continue working on follow-up. The methylation measures were conducted by the Australian Genome Research Facility (AGRF) in Melbourne. This work was supported by grants from the National Health and Medical Research Council (Grant number 1011618); and the Victorian Breast Cancer Research Consortium.